Stock Analiz

Anixa Biosciences Inc ANIX

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$2.62Market cap $91M
Open the interactive analysis →

Anixa Biosciences Inc (ANIX) is a healthcare company listed in the US with a market value of about $91M.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -43%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.

About Anixa Biosciences

Anixa Biosciences is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $4M in 2014 to $210000 in 2024, a decline of about 24.9% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 7% over three years (dilution for shareholders).

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B6.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−100%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-4393.4%
ROIC (5-yr avg.)-43.2%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue—$210000$210000—$512000—$250000$1M$362500$300000
Net income-$11M-$13M-$10M-$14M-$13M-$10M-$12M-$14M-$5M-$5M
Free cash flow—————-$6M-$5M-$4M-$4M-$4M
EPS (diluted)$-0.34$-0.39$-0.32$0.45$-450.00$-450.00$-590.00$-790.00$-580.00$-570.00
Net margin—-5978.1%-4671.9%—-2530.1%—-4658.8%-1258.1%-1381.8%-1672.1%
ROIC-60.2%-54.0%-35.5%-37.5%-29.1%-89.4%-179.4%-207.7%-60.6%-244.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Anixa Biosciences stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Anixa Biosciences pay a dividend?

Not currently.

Is Anixa Biosciences a good stock to buy?

We do not give buy or sell advice. Anixa Biosciences scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.